Castle Biosciences (CSTL) EBITDA Margin (2018 - 2026)
Castle Biosciences' (CSTL) quarterly EBITDA Margin came in at 22.0% in Q1 2026, up 974.0% year-on-year from 2.05% in Q1 2025, and down 400.12% quarter-over-quarter from 4.4% in Q4 2025.
Castle Biosciences (CSTL) EBITDA Margin (2018 - 2026) Analysis & Trends
Castle Biosciences has disclosed EBITDA Margin across 9 years of filings, most recently posting 22.0% for Q1 2026.
- EBITDA Margin for Q1 2026 came in at 22.0%, up 974.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 9.79% (down 582.0% YoY), and the FY2025 annual result was 12.44%, down 1505.0% from the prior year.
- EBITDA Margin came in at 22.0% for Q1 2026 at Castle Biosciences, down from 4.4% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 5.92% in Q3 2024 to a low of 91.7% in Q1 2022.
- The 5-year median for EBITDA Margin is 8.56% (2023), against an average of 24.59%.
- Across the five-year window, EBITDA Margin sank 7294 bps in 2022 and surged 6749 bps in 2024, its largest moves.
- Castle Biosciences' EBITDA Margin stood at 59.55% in 2022, then surged by 86 bps to 8.56% in 2023, then soared by 155 bps to 4.69% in 2024, then sank by 194 bps to 4.4% in 2025, then sank by 400 bps to 22.0% in 2026.
- The last three EBITDA Margin figures came in at 22.0% (Q1 2026), 4.4% (Q4 2025), and 8.19% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Waters | 30,529.42 Bn | 30,528.96 Bn | 1.11 Bn | -3.71% |
| 2 | Thermo Fisher Scientific | 183.75 Bn | 180.50 Bn | 7.74 Bn | 16.93% |
| 3 | Danaher | 133.13 Bn | 127.43 Bn | 3.59 Bn | 22.58% |
| 4 | Idexx Laboratories | 46.14 Bn | 45.94 Bn | 722.74 Mn | 31.78% |
| 5 | Agilent Technologies | 38.20 Bn | 36.39 Bn | 990.00 Mn | 21.74% |
| 6 | Natera | 31.50 Bn | 30.40 Bn | 696.04 Mn | -12.21% |
| 7 | Iqvia Holdings | 31.34 Bn | 29.36 Bn | 1.36 Bn | 12.38% |
| 8 | Illumina | 24.51 Bn | 23.36 Bn | 721.00 Mn | 19.16% |
| 9 | Mettler Toledo International | 23.53 Bn | 23.47 Bn | 555.82 Mn | 19.42% |
| 10 | Castle Biosciences | 629.76 Mn | 368.04 Mn | 63.15 Mn | -22.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.00% |
| Dec 31, 2025 | -4.40% |
| Sep 30, 2025 | -8.19% |
| Jun 30, 2025 | -4.93% |
| Mar 31, 2025 | -31.74% |
| Dec 31, 2024 | 4.69% |
| Sep 30, 2024 | 5.92% |
| Jun 30, 2024 | 5.76% |
| Mar 31, 2024 | -7.50% |
| Dec 31, 2023 | -8.56% |
| Sep 30, 2023 | -15.68% |
| Jun 30, 2023 | -42.20% |
| Mar 31, 2023 | -74.99% |
| Dec 31, 2022 | -59.55% |
| Sep 30, 2022 | -58.19% |
| Jun 30, 2022 | -4.73% |
| Mar 31, 2022 | -91.70% |
| Dec 31, 2021 | -25.68% |
| Sep 30, 2021 | -50.23% |
| Jun 30, 2021 | -38.63% |